Overview
DHEA (Dehydroepiandrosterone) is an endogenous adrenal steroid hormone and the most abundant circulating steroid in the human body. It functions as a prohormone—a precursor molecule that the body converts into more active hormones like testosterone, estrogen, and androstenediol. As a supplement, DHEA is primarily marketed as an anti-aging intervention, designed to counteract the dramatic age-related decline in DHEA levels that occurs naturally throughout life.
DHEA levels peak in the 20s and decline approximately 80% by age 70, which has prompted significant interest in supplementation to restore youthful hormone levels. While available over-the-counter in the United States, DHEA is a controlled or prescription substance in Canada, the UK, and most of Europe, reflecting regulatory concerns about its conversion to active sex hormones and associated health risks.
Beyond anti-aging claims, DHEA is studied for applications in adrenal insufficiency, depression, sexual dysfunction, bone density support, and vulvovaginal atrophy. Clinical evidence is most robust in postmenopausal women with adrenal insufficiency and in topical formulations for vaginal atrophy.
How It Works: Mechanism of Action
DHEA operates through multiple distinct pathways in the body:
Conversion to Sex Hormones
DHEA acts as a prohormone, peripherally converted to androgens (testosterone, androstenedione) and estrogens (estradiol, estrone) via tissue-specific steroidogenic enzymes. This localized conversion allows DHEA to exert hormonal effects without necessarily producing large systemic elevations in sex hormone concentrations—the body essentially "makes" active hormones where they're needed.
Direct Receptor Binding
Beyond conversion to sex hormones, DHEA binds directly to sigma-1 receptors, GABA-A receptors, and nuclear hormone receptors (including PPAR-alpha). These direct binding interactions exert neurosteroid, anti-glucocorticoid, and immune-modulatory effects independent of sex hormone conversion.
Metabolic and Inflammatory Effects
DHEA modulates insulin sensitivity, inflammatory cytokine production, and nitric oxide synthesis. These effects contribute to its reported benefits on metabolic health, cardiovascular function, and inflammatory markers.
Evidence by Health Goal
The following section outlines the current research evidence for DHEA across various health applications, organized by strength of evidence.
Fat Loss — Tier 3 Evidence
DHEA shows modest fat loss effects in human studies, though clinical significance remains debated.
A meta-analysis of 8+ randomized controlled trials found that DHEA supplementation decreased fat mass by 0.85% compared to placebo (95% CI: -1.18 to -0.51, p<0.001) and increased lean body mass by 0.45 kg (95% CI: 0.15 to 0.75, p=0.004). While statistically significant, these effect sizes are small. For example, a 200-pound individual might lose approximately 1.7 pounds of fat mass over the study period. The clinical relevance of such modest changes is debated among researchers and practitioners.
Muscle Growth — Tier 1 Evidence
DHEA supplementation for muscle growth lacks any human RCT evidence and should not be considered proven effective for this goal. While DHEA decline is associated with age-related muscle loss (sarcopenia), no supplementation trials have directly measured muscle growth outcomes in response to DHEA.
Injury Recovery — Tier 2 Evidence
DHEA shows promise for muscle recovery from exercise-induced damage, though evidence is limited.
One small human RCT in 16 young men found that DHEA 100 mg daily reduced creatine kinase (a marker of muscle damage) to a 3-fold increase versus a 9-fold increase in the placebo group during 5 days of mixed exercise training. Muscle soreness was significantly lower in the DHEA group on days 3 and 6 of training compared to placebo.
However, no human RCTs have tested DHEA in actual trauma or injury patients, limiting generalization beyond exercise-induced muscle damage.
Joint Health — Tier 2 Evidence
Evidence for joint health is plausible based on mechanistic review but unproven in human clinical trials.
An animal study in ovariectomized (osteoporotic) rats found that DHEA supplementation (5 mg/kg/day) improved bone mineral density, bone mineral content, and fracture callus remodeling compared to untreated osteoporotic controls at 3, 6, and 12 weeks post-fracture. However, two human RCTs measuring DHEA as part of weight loss and exercise interventions in 309 older adults with knee osteoarthritis did not directly test DHEA supplementation effects on joint outcomes.
Anti-Inflammation — Tier 2 Evidence
DHEA shows associations with reduced inflammation markers in observational studies, but direct proof from human supplementation trials is lacking.
A cross-sectional study of 119 aging men found that low DHEA-S levels were associated with elevated high-sensitivity C-reactive protein (hsCRP) and less favorable metabolic profiles, though causality was not established. A 2024 observational study noted that primary burning mouth syndrome patients had significantly higher salivary DHEA and cortisol compared to secondary BMS cases, suggesting DHEA may reflect inflammatory status rather than causally reducing inflammation.
Cognition — Tier 1 Evidence
Despite decades of research and theoretical rationale, DHEA supplementation has not been proven to improve cognitive function. A Cochrane meta-analysis found only three RCTs meeting inclusion criteria, and data pooling was not possible due to inconsistent results and lack of comparable statistics. An earlier Cochrane review searched 415 studies but found insufficient evidence of benefit for cognitive function or dementia in older adults.
Mood & Stress — Tier 2 Evidence
DHEA shows plausible mechanisms for mood and stress modulation but lacks robust human RCT evidence.
A meta-analysis found that in women with primary or secondary adrenal insufficiency or anorexia, DHEA showed "small benefits in quality of life and mood" but not for anxiety. No consistent benefits were observed in women with normal adrenal function. A correlational study in 119 healthy older adults found that higher dispositional optimism correlated with lower hair cortisol and a lower cortisol/DHEA ratio (β = -0.256, p = .008), though this does not establish causality.
Sleep — Tier 2 Evidence
DHEA's effects on sleep have not been directly demonstrated in clinical trials, though observational associations exist.
A large observational cohort of 6,465 men age 50+ found that those with greater sleep disturbance had significantly lower DHEA-S levels (P=0.016). In a crossover RCT of 50 mg DHEA daily in 46 older men, higher evening DHEA was associated with lower anxiety (r=-0.35; P=0.03), and higher morning DHEA was associated with lower confusion (r=-0.33; P=0.04). These associations suggest DHEA may relate to sleep quality, but no RCT has proven that DHEA supplementation improves sleep onset, duration, or quality.
Longevity — Tier 2 Evidence
DHEA levels decline with age, but human evidence for supplementation improving lifespan is absent—and recent data suggest caution.
A Mendelian randomization study (a design that aims to establish causality) found that DHEA-S was associated with 1.15 years shorter lifespan in men (95% CI -1.72 to -0.58, n=4,327), with no effect in women (0.04 years, 95% CI -0.50 to 0.58, n=3,501). This contradicts the anti-aging hypothesis. Additionally, the cortisol/DHEA-S ratio was identified as the best predictor of epigenetic age acceleration across six epigenetic clocks in 969 individuals, suggesting DHEA's role in aging is context-dependent and modulated by cortisol.
Immune Support — Tier 2 Evidence
DHEA shows immunomodulatory effects in laboratory and animal studies, with some evidence in elderly populations, but robust human RCT evidence demonstrating clinically meaningful immune benefits is absent.
Reviews of RCTs in elderly subjects note that DHEA increases monocytes, TCRγδ+ T cells, and natural killer cell populations. In adrenal insufficiency patients, DHEA restores normal CD4+CD25(hi) and FoxP3 levels and improves immune regulation. However, most claims remain theoretical or based on mechanistic studies rather than proof of clinical efficacy.
Energy & Metabolic Function — Tier 2 Evidence
DHEA shows mechanistic promise for improving mitochondrial energy production, particularly in aging contexts, but robust human evidence is limited.
A human RCT in infertile aging women undergoing IVF found that DHEA shifted cumulus cells from anaerobic to aerobic metabolism and increased mitochondrial oxygen consumption, associated with improved pregnancy rates and embryo quality. A double-blind, placebo-controlled RCT in 280 healthy adults aged 60-79 found that after 1 year of DHEA 50 mg daily, increased libido was significantly noted in older women, and youthful DHEA-S levels were reestablished with no harmful hormone accumulation.
Skin & Hair — Tier 3 Evidence
Topical DHEA shows evidence of improving skin aging markers, but oral DHEA lacks robust evidence and may cause androgenic side effects.
Gene expression analysis found dose-dependent increases in collagen genes (COL1, COL3, COL5) and upregulation of SPARC (required for collagen maturation) with topical 0.3–2% DHEA in 60 postmenopausal women. A separate RCT found that topical DHEA cream (0.1–2%) increased androgen receptor expression markedly and increased procollagen 1 and 3 mRNA in the dermis of postmenopausal women (n=75).
However, one RCT of oral DHEA in fibromyalgia patients found androgenic side effects (acne, greasy skin, increased body hair) without clinical benefit.
Gut Health — Tier 1 Evidence
No evidence that DHEA improves gut health. Available studies examine DHEA's effects on cancer, fertility, mental health, aging, and steroid metabolism—none directly test gut health as a primary outcome.
Heart Health — Tier 2 Evidence
DHEA/DHEA-S levels are associated with cardiovascular health in observational studies, but no human RCTs demonstrate that supplementation improves heart outcomes.
A large observational study (n=8,143, 18-year follow-up) found that low DHEA-S (below the 15th percentile) was associated with increased heart failure hospitalization: men HR 1.30 (95% CI 1.07–1.58) and women HR 1.42 (95% CI 1.13–1.79). Low DHEA-S was also associated with increased mortality: men HR 1.12 (95% CI 1.01–1.25) and women HR 1.19 (95% CI 1.03–1.37). These associations are compelling but do not prove that supplementation would reverse these risks.
Liver Health — Tier 2 Evidence
DHEA does not improve liver function but appears safe for liver tissue.
A meta-analysis of 10 RCT arms found no significant effect of DHEA supplementation on AST (WMD: -3.7 U/L, 95% CI: -10.35 to 2.95, p=0.276) or ALT (WMD: -1.7 U/L, 95% CI: -3.45 to 0.06, p=0.058). An RCT in Sheehan syndrome (n=28) found DHEA 50 mg daily for 3 months showed no significant changes in liver enzyme levels. DHEA is safe for the liver, but safety is not efficacy.
Hormonal Balance — Tier 2 Evidence
DHEA levels decline with age and observational studies correlate this with various changes, but human RCT evidence in healthy adults is extremely limited.
The only human RCT (n=39 healthy older men) found that 100 mg DHEA daily for 3 months produced mild, temporary changes in blood chemistry and endocrine parameters but no improvements in lean body mass, body composition, sexual function, or psychological well-being. All changes reversed after cessation. Observational evidence confirms that DHEA and DHEA-S concentrations decline steadily from age 40–45 through 65–69 in women.
Sexual Health — Tier 3 Evidence
DHEA shows modest improvements in sexual function in specific populations but evidence is limited by small sample sizes and lack of consistent effects.
In Sheehan syndrome, DHEA 50 mg daily for 3 months significantly improved FSFI (Female Sexual Function Index) score versus placebo (P=0.006, n=28), with improvements in desire, arousal, and satisfaction domains. In infertile women, DHEA 75 mg daily for 4-8 weeks increased total FSFI score by 7% (from 27.2 to 29.2, P=0.0166, n=50), with desire increasing 17% (P=0.0004) and arousal increasing 12% (P=0.0122).
Athletic Performance — Tier 3 Evidence
DHEA shows mixed but moderately positive evidence for athletic performance, particularly when combined with resistance exercise in older adults.
A meta-analysis of 22 RCTs in older adults found low- to moderate-quality evidence that regular physical activity beneficially reduces cortisol and increases DHEA(S) levels. One study (n=56) found that 4 months of weightlifting combined with 10 months of DHEA replacement potentiated gains in muscle strength (measured by 1-RM and Cybex dynamometry) and thigh muscle volume versus exercise plus placebo alone.